Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER_GOV 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Lymphoid 1

Conditions

Sarcoma, Kaposi 4Acquired Immunodeficiency Syndrome 2Sarcoma 1Multi-centric Castleman's Disease 1Immune Reconstitution Inflammatory Syndrome 1Castleman Disease 1

Interventions

Zidovudine 10Doxorubicin 10Vincristine 7Bleomycin 7Liposomes 5Interferon alpha-2 5tecogalan 4Etoposide 3sargramostim 2pomalidomide 2liposomal doxorubicin 2interferon alfa-n1 2Valganciclovir 2Ritonavir 2Paclitaxel 2Nivolumab 2Mitoxantrone 2Didanosine 2vesnarinone 1tocilizumab 1tin etiopurpurin 1abemaciclib 1Zalcitabine 1Tumor Necrosis Factor-alpha 1Sorafenib 1Semaxinib 1Ro 24-7429 1O-(Chloroacetylcarbamoyl)fumagillol 1Nevirapine 1Muromonab-CD3 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Acquired Immunodeficiency Syndrome × Valganciclovir × Sarcoma × Clear all
NCT03296553 2022-01-27

Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.

National Institute of Cancerología

Phase 2 Completed
40 enrolled 6 charts
Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, Immune Reconstitution Inflammatory Syndrome

NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
8 enrolled 18 charts
LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon ⚡